Clinical Trial Update: PEG-interferon Alfa-2a add-on Study in HBeAg Negative Chronic Hepatitis B Patients [Phase 4]

View source ↗

Summary

Phase 4 clinical trial update evaluating PEG-interferon alfa-2a as an add-on in HBeAg-negative chronic hepatitis B patients.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis B

Drugs mentioned

• PEG-interferon alfa-2a (pegylated interferon alfa-2a)

Snippet

Sponsor: Foundation for Liver Research | Conditions: Chronic Hepatitis B | Phase 4 | Status: COMPLETED